| dbo:abstract
|
- Le ximélagatran (en France et en Suisse : Exanta)(usage oral) était un médicament anticoagulant oral direct, prodrogue du mélagatran (usage sous-cutané). Le 14 février 2006, ce médicament a été retiré du marché au niveau mondial.. Son producteur voit en lui un remplaçant des anti-vitamines K, soumis aux aléas de la nutrition, de l'interaction médicamenteuse, et du monitoring (suivi sanguin). (fr)
- Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would withdraw pending applications for marketing approval after reports of hepatotoxicity (liver damage) during trials, and discontinue its distribution in countries where the drug had been approved (Germany, Portugal, Sweden, Finland, Norway, Iceland, Austria, Denmark, France, Switzerland, Argentina and Brazil). (en)
- Ximelagtran è un farmaco anticoagulante appartenente alla nuova categoria degli inibitori diretti della trombina, detti anche: Nuovi anticoagulanti orali (NAO). Il farmaco, prodotto dalla astraZeneca, è stato nel 2006ritirato dal commercio per problemi di tossicità epatica. (it)
- Ximelagatran (Exanta® of Exarta®, H 376/95) was het eerste orale antistollingsmiddel dat uitgebreid onderzocht werd als een alternatief voor de vitamine K- antagonisten. In 2006 kondigde de fabrikant AstraZeneca aan dat ze na meldingen van hepatotoxiciteit (leverschade) het middel zou terugtrekken. De firma stopte de distributie in landen waar het geneesmiddel al was goedgekeurd. Duitsland, Portugal, Zweden, Finland, Noorwegen, IJsland, Oostenrijk, Denemarken, en Frankrijk (nl)
- Ximelagatrana é um fármaco que age como inibidor direto da trombina. (pt)
|
| dbo:alternativeName
| |
| dbo:bioavailability
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 10943 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:bioavailability
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:iupacName
|
- ethyl 2-(1R)-1-cyclohexyl-2-[(2S)-2-[[4-(N'-hydroxycarbamimidoyl)phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxo-ethyl]amino]acetate (en)
|
| dbp:iupharLigand
| |
| dbp:kegg
| |
| dbp:legalStatus
|
- Withdrawn from market (en)
|
| dbp:metabolism
| |
| dbp:molecularWeightComment
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyCategory
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Le ximélagatran (en France et en Suisse : Exanta)(usage oral) était un médicament anticoagulant oral direct, prodrogue du mélagatran (usage sous-cutané). Le 14 février 2006, ce médicament a été retiré du marché au niveau mondial.. Son producteur voit en lui un remplaçant des anti-vitamines K, soumis aux aléas de la nutrition, de l'interaction médicamenteuse, et du monitoring (suivi sanguin). (fr)
- Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would withdraw pending applications for marketing approval after reports of hepatotoxicity (liver damage) during trials, and discontinue its distribution in countries where the drug had been approved (Germany, Portugal, Sweden, Finland, Norway, Iceland, Austria, Denmark, France, Switzerland, Argentina and Brazil). (en)
- Ximelagtran è un farmaco anticoagulante appartenente alla nuova categoria degli inibitori diretti della trombina, detti anche: Nuovi anticoagulanti orali (NAO). Il farmaco, prodotto dalla astraZeneca, è stato nel 2006ritirato dal commercio per problemi di tossicità epatica. (it)
- Ximelagatran (Exanta® of Exarta®, H 376/95) was het eerste orale antistollingsmiddel dat uitgebreid onderzocht werd als een alternatief voor de vitamine K- antagonisten. In 2006 kondigde de fabrikant AstraZeneca aan dat ze na meldingen van hepatotoxiciteit (leverschade) het middel zou terugtrekken. De firma stopte de distributie in landen waar het geneesmiddel al was goedgekeurd. Duitsland, Portugal, Zweden, Finland, Noorwegen, IJsland, Oostenrijk, Denemarken, en Frankrijk (nl)
- Ximelagatrana é um fármaco que age como inibidor direto da trombina. (pt)
|
| rdfs:label
|
- Ximélagatran (fr)
- Ximelagatran (it)
- Ximelagatran (nl)
- Ximelagatrana (pt)
- Ximelagatran (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
